Mustang Bio (NASDAQ:MBIO) Issues Quarterly Earnings Results

Mustang Bio (NASDAQ:MBIO) issued its quarterly earnings results on Thursday. The company reported ($0.07) EPS for the quarter, FiscalAI reports.

Mustang Bio Trading Down 1.1%

MBIO stock traded down $0.01 during midday trading on Thursday, hitting $0.85. The stock had a trading volume of 64,483 shares, compared to its average volume of 192,985. The stock has a 50-day simple moving average of $0.95 and a 200 day simple moving average of $1.22. The firm has a market capitalization of $6.20 million, a price-to-earnings ratio of -2.74 and a beta of 2.13. Mustang Bio has a 52 week low of $0.53 and a 52 week high of $7.00.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Mustang Bio stock. Kestra Advisory Services LLC raised its stake in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 111,042 shares of the company’s stock after acquiring an additional 44,934 shares during the quarter. Kestra Advisory Services LLC owned approximately 1.52% of Mustang Bio worth $109,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mustang Bio in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Mustang Bio Company Profile

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.